H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines.

Abstract

Simple SummaryAlthough the involvement of the H3.3K27M mutation in Diffuse Midline Glioma tumorigenesis is now established, its role in their resistance to treatments and, therefore, in their fatal outcome remains poorly documented. Here, thanks to our models of H3.3K27M induction in pediatric glioma cells, we finally shed light on this crucial issue. Hence, we demonstrate here for the first time that H3.3K27M can increase cell radioresistance capabilities independently of TP53 alterations. Moreover, thanks to a drug library screening, we evidenced that this mutation can, depending on the cellular context, drastically modulate the response of these cells to different classes of compounds, thus paving the way for new therapeutic strategies. Altogether, our results provide here the proof that, beyond its role in tumorigenesis, the presence of H3.3K27M mutation by itself alters the response to treatments of pediatric glioma cells.High-grade gliomas represent the most lethal class of pediatric tumors, and their resistance to both radio- and chemotherapy is associated with a poor prognosis. Recurrent mutations affecting histone genes drive the tumorigenesis of some pediatric high-grade gliomas, and H3K27M mutations are notably characteristic of a subtype of gliomas called DMG (Diffuse Midline Gliomas). This dominant negative mutation impairs H3K27 trimethylation, leading to profound epigenetic modifications of genes expression. Even though this mutation was described as a driver event in tumorigenesis, its role in tumor cell resistance to treatments has not been deciphered so far. To tackle this issue, we expressed the H3.3K27M mutated histone in three initially H3K27-unmutated pediatric glioma cell lines, Res259, SF188, and KNS42. First, we validated these new H3.3K27M-expressing models at the molecular level and showed that K27M expression is associated with pleiotropic effects on the transcriptomic signature, largely dependent on cell context. We observed that the mutation triggered an increase in cell growth in Res259 and SF188 cells, associated with higher clonogenic capacities. Interestingly, we evidenced that the mutation confers an increased resistance to ionizing radiations in Res259 and KNS42 cells. Moreover, we showed that H3.3K27M mutation impacts the sensitivity of Res259 cells to specific drugs among a library of 80 anticancerous compounds. Altogether, these data highlight that, beyond its tumorigenic role, H3.3K27M mutation is strongly involved in pediatric glioma cells’ resistance to therapies, likely through transcriptomic reprogramming.